Standard treatments induce antigen-specific immune responses in prostate cancer.
Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P, Pai H, Ludgate C, Nelson BH.
Nesslinger NJ, et al.
Clin Cancer Res. 2007 Mar 1;13(5):1493-502. doi: 10.1158/1078-0432.CCR-06-1772.
Clin Cancer Res. 2007.
PMID: 17332294